Zhao Xiao-Dong, He Jun-Hua, Wang Zu-Heng, Xu Song
Jinling School of Clinical Medicine, Nanjing Medical University, Nanjing, Jiangsu 210002, China.
Department of Gynecology and Obstetrics, General Hospital of Eastern Theater Command, Nanjing, Jiangsu 210002, China.
Zhonghua Nan Ke Xue. 2022 Jul;28(7):635-641.
Prostate cancer (PCa) is a most common malignancy in the genitourinary system, which imposes a huge burden on the patients and society. Various traditional medication methods fail to achieve satisfactory effects, and therefore it is imperative to develop innovative and effective routes of administration. Drug delivery systems have the characteristics of both delivery and controlled release and are widely used clinically. Prostate-specific membrane antigen (PSMA) is one of the most characteristic and highly selective biomarkers of PCa with a good PCa-targetability. Many drug delivery systems targeting PSMA have been explored, including drug-ligand conjugates and nano-drug delivery systems (polymer nanoparticles, inorganic nanoparticles, liposomes, and biological nanoparticles, etc.). This article reviews the recent studies on the role of the PSMA-targeting drug delivery system in PCa, in order to provide some reference for the precise and effective treatment of the malignancy.
前列腺癌（PCa）是泌尿生殖系统中最常见的恶性肿瘤，给患者和社会带来了巨大负担。各种传统药物治疗方法均未能取得令人满意的效果，因此开发创新且有效的给药途径势在必行。药物递送系统具有递送和控释的特性，在临床上得到广泛应用。前列腺特异性膜抗原（PSMA）是PCa最具特征性和高度选择性的生物标志物之一，具有良好的PCa靶向性。人们已经探索了许多靶向PSMA的药物递送系统，包括药物-配体偶联物和纳米药物递送系统（聚合物纳米颗粒、无机纳米颗粒、脂质体和生物纳米颗粒等）。本文综述了PSMA靶向药物递送系统在PCa中的作用的最新研究，以便为该恶性肿瘤的精准有效治疗提供一些参考。
